MP-10.21

Randomized controlled trials are currently conducted to assess whether the mortality from prostate cancer is reduced by early detection using prostate specific antigen (PSA) measurements in serum. To be effective, such a program should be able to reduce the absolute number of men diagnosed with metastatic prostate cancer (where no cure is available). The aim of the present report is to evaluate whether PSA-based screening reduces the risk of being diagnosed with metastatic prostate cancer.